Coherus Oncology, Inc. — Operating Income by Fiscal Year
14 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/b0de84d9-1803-407e-9d8f-83494650e839/serie/operating-income
| Fiscal year | Operating Income | Period | Evidence |
|---|---|---|---|
| FY 2025 | $-181.1M | 2025-01-01 – 2025-12-31 | evidence 0001104659-26-025308 |
| FY 2024 | $-199.7M | 2024-01-01 – 2024-12-31 | evidence 0001104659-25-111484 |
| FY 2023 | $-215.8M | 2023-01-01 – 2023-12-31 | evidence 0001104659-25-111484 |
| FY 2022 | $-256.9M | 2022-01-01 – 2022-12-31 | evidence 0001558370-23-002917 |
| FY 2021 | $-263.9M | 2021-01-01 – 2021-12-31 | evidence 0001558370-22-001764 |
| FY 2020 | $156.3M | 2020-01-01 – 2020-12-31 | evidence 0001558370-21-001829 |
| FY 2019 | $107.8M | 2019-01-01 – 2019-12-31 | evidence 0001564590-20-007416 |
| FY 2018 | $-204.4M | 2018-01-01 – 2018-12-31 | evidence 0001564590-19-005470 |
| FY 2017 | $-232.1M | 2017-01-01 – 2017-12-31 | evidence 0001564590-18-004947 |
| FY 2016 | $-115.9M | 2016-01-01 – 2016-12-31 | evidence 0001564590-17-004176 |
| FY 2015 | $-219.1M | 2015-01-01 – 2015-12-31 | evidence 0001564590-16-013726 |
| FY 2014 | $-64.7M | 2014-01-01 – 2014-12-31 | evidence 0001564590-15-001896 |
| FY 2013 | $-36.0M | 2013-01-01 – 2013-12-31 | evidence 0001564590-15-001896 |
| FY 2012 | $-38.5M | 2012-01-01 – 2012-12-31 | evidence 0001564590-15-001896 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).